Mirum Pharmaceuticals, Inc. Common Stock

MIRM XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

5.6B

Short interest (May 15)

13.4%

Net Short (Jun 03 ): 0.0%

Borrow Fee

0.40%

↓ 7.2%

Available Shares

600K

↑ 37.5%

Price Chart

Company Overview

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001759425

Asset Type: CS

Market Data

Market Cap: $5,620,639,692

Employees: 418

Status: Active

Short Interest

Current Borrow Fee 0.40%

Range: 0.25% - 0.40%

Available Shares 600K

Range: 550K - 650K

Recent Changes

Fee Change: ↓ 7.9%

Available Change: ↓ 11.1%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime